Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 13 March 2007. doi:10.1136/thx.2006.068114
Thorax 2007;62:569-576
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
thx.2006.068114v1
62/7/569    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Creaney, J.
Right arrow Articles by Robinson, B. W S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Creaney, J.
Right arrow Articles by Robinson, B. W S
Topic Collections
Right arrow Editor's choice
Right arrowRelevant Articles

LUNG CANCER

Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma

Jenette Creaney1,2, Deborah Yeoman1, Leanne K Naumoff1, Michelle Hof1,2, Amanda Segal3, Arthur William Musk1,4, Nicholas De Klerk1,5, Nora Horick, Steven J Skates, Bruce W S Robinson1,2

1 National Research Centre for Asbestos Related Diseases, Western Australian Institute of Medical Research, University of Western Australia, Sir Charles Gairdner Hospital, Perth, Australia
2 Australian Mesothelioma Tissue Bank, Sir Charles Gairdner Hospital, Perth, Australia
3 PathWest Laboratory Medicine WA, Queen Elizabeth II Medical Centre, Perth, Australia
4 Department of Respiratory Medicine, Sir Charles Gairdner Hospital, Perth, Australia
5 Telethon Institute of Child Health Research, Subiaco, AustraliaBiostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA

Correspondence to:
Correspondence to:
Dr Jenette Creaney
Department of Medicine and Pharmacology, University of Western Australia, Sir Charles Gairdner Hospital, Verdun Ave, Nedlands, 6009, Western Australia, Australia; creaneyj{at}cyllene.uwa.edu.au

Background: The diagnosis of malignant mesothelioma is frequently difficult, the most common differential diagnosis being reactive pleural conditions and metastatic adenocarcinoma. Soluble mesothelin levels in serum have recently been shown to be highly specific and moderately sensitive for mesothelioma. As most patients with mesothelioma present with exudative effusions of either the pleura or the peritoneum, a study was undertaken to determine if levels of mesothelin were raised in these fluids and if the increased levels could help to distinguish mesothelioma from other causes of exudative effusion.

Methods: Pleural fluid was collected from 192 patients who presented to respiratory clinics (52 with malignant mesothelioma, 56 with non-mesotheliomatous malignancies and 84 with effusions of non-neoplastic origin). Peritoneal fluid was collected from 42 patients (7 with mesothelioma, 14 with non-mesotheliomatous malignancies and 21 with benign effusions). Mesothelin levels were determined in effusion and serum samples by ELISA.

Results: Significantly higher levels of mesothelin were found in effusions of patients with mesothelioma; with a specificity of 98%, the assay had a sensitivity of 67% comparing patients with mesothelioma and those with effusions of non-neoplastic origin. In 7 out of 10 cases mesothelin levels were raised in the effusion collected 3 weeks to 10 months before the diagnosis of mesothelioma was made; in 4 out of 8 of these, mesothelin levels were increased in the effusion but not in the serum.

Conclusions: Measurement of mesothelin concentrations in the pleural and/or peritoneal effusion of patients may aid in the differential diagnosis of mesothelioma in patients presenting with effusions.


Abbreviations: CA, cancer antigen; CEA, carcinoembryonic antigen; CYFRA, cytokine fragment; ROC, receiver operating characteristic


Relevant Articles

Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?
Y C Gary Lee
Thorax 2007 62: 561-562. [Extract] [Full Text] [PDF]

AIRWAVES
Wisia Wedzicha
Thorax 2007 62: 561. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
K. Matsushita, I. Margulies, M. Onda, S. Nagata, M. Stetler-Stevenson, and R. J. Kreitman
Soluble CD22 as a tumor marker for hairy cell leukemia
Blood, September 15, 2008; 112(6): 2272 - 2277.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
M. D. Johnson, F. Vito, and M. J. O'Connell
Mesothelin Expression in the Leptomeninges and Meningiomas
J. Histochem. Cytochem., June 1, 2008; 56(6): 579 - 585.
[Abstract] [Full Text] [PDF]


Home page
ThoraxHome page
J Creaney, B Musk, N De Klerk, and B W Robinson
Authors' reply
Thorax, January 1, 2008; 63(1): 87 - 87.
[Full Text] [PDF]


Home page
ThoraxHome page
B D Grigoriu and A Scherpereel
Diagnostic value of soluble mesothelin in malignant mesothelioma
Thorax, January 1, 2008; 63(1): 87 - 88.
[Full Text] [PDF]


Home page
ThoraxHome page
Y C G. Lee
Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?
Thorax, July 1, 2007; 62(7): 561 - 562.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2007 BMJ Publishing Group Ltd & British Thoracic Society